May 8, 2017
Ipsen buys five Sanofi’s products
Ipsen has completed acquisition of a portfolio of five consumer healthcare products from Sanofi.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
May 8, 2017
IDMC gives green light for extension of Faron Pharmaceuticals’s rare lung disease
Faron Pharmaceuticals has received the Independent Data Monitoring Committee’s (IDMC) recommendation to continue the INTEREST Phase III study for the treatment of patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) with its lead product Traumakine.
May 5, 2017
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
MDxHealth has signed an agreement with the Faculty of Health, Medicine and Life Sciences / School for Oncology and Developmental Biology (GROW) at Maastricht University to expand its existing research collaboration to develop commercial next generation (epi)genetic cancer diagnostics.
May 5, 2017
Genfit enrolls first patients in its liver disease drug test
Genfit, a biopharmaceutical company focused on developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, has started patient testing in the Phase 2a trial evaluating elafibranor in PBC.
May 4, 2017
Karo Pharma reaches second milestone from collaboration with Pfizer
Karo Pharma has reached a second milestone from its collaboration with Pfizer on the RORgamma project amounting to $2 million.
May 4, 2017
Mereo BioPharma starts Phase 2 study of rare bone disease drug
Mereo BioPharma Group, a clinical stage, biopharmaceutical company focused on rare and specialty diseases, has initiated a potentially pivotal Phase 2b clinical study of BPS-804 for the treatment of the orphan disease, osteogenesis imperfecta (OI) (brittle bone disease), the ASTEROID study.
May 4, 2017
CTI BioPharma reports $19.8M loss
CTI BioPharma has reported net loss of $19.8 million for the first quarter of 2017. The loss is decrease compared to the profit of $3.3 million for the same period in 2016.
May 4, 2017
Sobi welcomes new CEO
Swedish Orphan Biovitrum (Sobi) has appointed Guido Oelkers as President and Chief Executive Officer effective as of 22 May 2017, succeeding Geoffrey McDonough.
May 3, 2017
Novo Nordisk reports 10% profit increase for Q1 2017
Novo Nordisk has reported profit of €1.4 billion for the first quarter of 2017, which is increase of 10%.
May 3, 2017
Sobi with new haemophilia research office in Greece
Swedish Orphan Biovitrum (Sobi) will open a new office in Athens, Greece.